MAPT and Parkinson disease: Almgren et al. (2023) investigated the use of multimodal features, including CSF-based biomarkers, (such as total-tau, phosphorylated-tau, Aβ42, and alpha-synuclein) and MRI-based volumetric data to predict cognitive decline in subjects with PD (n = 213).